Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study.

CONCLUSION: Gemcitabine and ipilimumab is a safe and tolerable regimen for PDAC with a similar response rate to gemcitabine alone. As in other immunotherapy trials, responses were relatively durable in this study.
IMPLICATIONS FOR PRACTICE: Gemcitabine and ipilimumab is a safe and feasible regimen for treating advanced pancreatic cancer. Although one patient in this study had a relatively durable response of nearly 20 months, adding ipilimumab to gemcitabine does not appear to be more effective than gemcitabine alone in advanced pancreatic cancer.
PMID: 31740568 [PubMed - as supplied by publisher]

Source: The Oncologist - November 17, 2019 Category: Cancer & Oncology Authors: Kamath SD, Kalyan A, Kircher S, Nimeiri H, Fought AJ, Benson A, Mulcahy M Tags: Oncologist Source Type: research